Company Filing History:
Years Active: 2002
Title: The Innovative Contributions of Micheal M Wick in Cancer Treatment
Introduction
Micheal M Wick, an accomplished inventor based in Woodside, California, is recognized for his significant contributions to the medical field, particularly in cancer treatment. With an innovative approach to addressing diseases linked to the insulin growth factor-1 receptor (IGF-1R), Wick's work holds the potential to influence therapeutic methods significantly.
Latest Patents
Micheal M Wick holds one patent titled "Heteroaryl-aryl ureas as IGF-1 receptor antagonists." This patent outlines methods for treating diseases associated with the IGF-1R. The invention focuses on inhibiting cell growth and proliferation, particularly in tumor cells, while promoting apoptosis. The use of heteroaryl-aryl urea compounds as antagonists for IGF-1R presents a promising avenue for developing effective cancer treatments.
Career Highlights
Wick is affiliated with Telik, Inc., a company dedicated to innovation in drug development and therapeutic solutions. His work at Telik has been pivotal in advancing research and creating new methodologies for treating cancers, showcasing his dedication to improving patient outcomes through scientific innovation.
Collaborations
Throughout his career, Micheal M Wick has collaborated with esteemed colleagues such as Michael R Kozlowski and Robert T Lum. These collaborations have further enhanced the research capabilities at Telik, driving forward the mission to pioneer effective cancer therapies.
Conclusion
Micheal M Wick's contributions to the field of medical research and cancer treatment through his patent demonstrate the power of innovation in addressing complex health challenges. His ongoing work at Telik, Inc., alongside his collaborators, reinforces the importance of teamwork in advancing scientific knowledge and developing effective solutions for diseases such as cancer.